Kirk Campbell, MD
Nephrology · New York, NYNPI 1184761389
Payments from drug & device makers
Across 275 payments — averaging $4029.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$290K
- Aurinia Pharma U.S., Inc.$201K
- Astrazeneca UK Limited$164K
- Mallinckrodt Hospital Products Inc.$136K
- Novartis$117K
- Vertex$91K
- plus $110K from 13 others
Across 1 payment — averaging $7228.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 153 | $290,474 |
| Aurinia Pharma U.S., Inc. | 6 | $200,510 |
| Astrazeneca UK Limited | 14 | $164,085 |
| Mallinckrodt Hospital Products Inc. | 8 | $135,921 |
| Novartis | 29 | $116,740 |
| Vertex | 8 | $90,847 |
| Mallinckrodt Enterprises LLC | 14 | $47,299 |
| Boehringer Ingelheim | 11 | $18,585 |
| Calliditas Therapeutics US Inc. | 10 | $12,526 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $11,133 |
| ANI Pharmaceuticals, Inc. | 3 | $6,150 |
| Orion Corporation | 2 | $4,250 |
| Astrazeneca AB | 4 | $3,500 |
| Sanofi US Services Inc. | 1 | $3,000 |
| Sanofi | 1 | $1,274 |
| Amgen | 1 | $1,100 |
| AstraZeneca | 1 | $670 |
| Novo Nordisk | 3 | $133 |
| Salvin Dental Specialties, Inc. | 1 | $47 |
How this compares
$1,108,242 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in New York
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Jai RadhakrishnanNew York$995K
- Girish NadkarniNew York$978K
- David GoldfarbNew York$808K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.